Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of Cilastatin for the prevention of AKI in human diseases outside of the COVID-19 pandemic

Trial Profile

Phase II trial of Cilastatin for the prevention of AKI in human diseases outside of the COVID-19 pandemic

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Arch Biopartners
  • Most Recent Events

    • 28 Feb 2024 Accoring to Arch Biopartners media release, the company is acting as an industry partner with clinical researchers in Canada and the United States who are planning to conduct two separate phase II clinical studies respectively for toxin-related AKI in late 2024.
    • 19 Apr 2021 New trial record
    • 15 Apr 2021 According to an Arch Biopartners media release, the company has has entered into an exclusive worldwide license agreement with Telara Pharma of Spain to clinically develop and market cilastatin for the treatment and prevention of acute kidney injury.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top